Skip to main
IVA

Inventiva S.A. (IVA) Stock Forecast & Price Target

Inventiva S.A. (IVA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inventiva SA is a biopharmaceutical company focused on developing lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH), addressing a significant unmet medical need as there are currently no approved therapies for this condition. The encouraging clinical trial data shows that lanifibranor may provide considerable benefits, including fibrosis improvement and metabolic advantages, positioning it as a potentially best-in-class treatment that could enhance its market adoption in endocrinology and cardiometabolic clinics. Additionally, strong revenue generation from research partnerships with AbbVie and BI supports Inventiva's financial stability and growth potential in its clinical-stage research operations.

Bears say

Inventiva SA, a biopharmaceutical company focused on the development of therapies for diseases like NASH, is facing a negative outlook primarily due to significant financial losses, reporting a net loss of €175.9 million, or €1.62 per share. The company's lead product candidate, lanifibranor, is currently in Phase III development, where any adverse efficacy or safety concerns could severely impact share performance and investor confidence. Additional risks include delays in regulatory timelines and challenges in accessing sufficient financing, which may hinder the company's ability to execute its planned operations effectively.

Inventiva S.A. (IVA) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inventiva S.A. (IVA) Forecast

Analysts have given Inventiva S.A. (IVA) a Buy based on their latest research and market trends.

According to 8 analysts, Inventiva S.A. (IVA) has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inventiva S.A. (IVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.